{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:35:15Z","timestamp":1782300915087,"version":"3.54.5"},"reference-count":22,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2019,5,16]]},"published-print":{"date-parts":[[2019,5,31]]},"abstract":"<jats:p>A 14-year-old boy with familial Li-Fraumeni syndrome presented with diplopia. Brain MRI revealed a right temporoparietal rim-enhancing mass. Following surgical resection and diagnosis of a gigantocellular-type glioblastoma multiforme (GBM), his family wished to avoid cytotoxic chemotherapy given the amplified risk of secondary malignancy. As such, we performed whole exome and transcriptome sequencing, which revealed germline <jats:italic>TP53<\/jats:italic> and somatic <jats:italic>TSC2<\/jats:italic> mutations. On completion of adjuvant radiotherapy, he was started on maintenance therapy with everolimus per recommendations from our multi-institutional brain tumour precision medicine tumour board. He has achieved a complete remission with resolution of visual symptoms and remains on everolimus therapy with concurrent electromagnetic field therapy, now 33 months from diagnosis. Our data highlight the benefit of precision medicine in children with GBM and offer insight into a targetable pathway that may be involved in similar cases.<\/jats:p>","DOI":"10.1136\/bcr-2018-227734","type":"journal-article","created":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T07:44:01Z","timestamp":1559375041000},"page":"e227734","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":18,"title":["Successful treatment of a <i>TSC2<\/i>-mutant glioblastoma with everolimus"],"prefix":"10.1136","volume":"12","author":[{"given":"Andrew H","family":"Zureick","sequence":"first","affiliation":[{"name":"University of Michigan Medical School, Michigan Medicine, Ann Arbor, Michigan, USA"},{"name":"Department of Radiation Oncology, Beaumont Health System, Royal Oak, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn A","family":"McFadden","sequence":"additional","affiliation":[{"name":"Department of Pathology, Michigan Medicine, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajen","family":"Mody","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology, Department of Pediatrics, Michigan Medicine, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0825-7615","authenticated-orcid":false,"given":"Carl","family":"Koschmann","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology, Department of Pediatrics, Michigan Medicine, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,5,31]]},"reference":[{"key":"2025082803555950000_12.5.e227734.1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-016-1545-1"},{"key":"2025082803555950000_12.5.e227734.2","first-page":"1165","article-title":"Pediatric glioblastoma with giant cells and \"supratentorial\" primitive neuroectodermal component - case report and review of the literature","volume":"56","author":"Georgiu","year":"2015","journal-title":"Rom J Morphol Embryol"},{"key":"2025082803555950000_12.5.e227734.3","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3655"},{"key":"2025082803555950000_12.5.e227734.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043330"},{"key":"2025082803555950000_12.5.e227734.5","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now038"},{"key":"2025082803555950000_12.5.e227734.6","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19890201)63:3<524::AID-CNCR2820630321>3.0.CO;2-D"},{"key":"2025082803555950000_12.5.e227734.7","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-2008-123"},{"key":"2025082803555950000_12.5.e227734.8","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-2008-099"},{"key":"2025082803555950000_12.5.e227734.9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00381-015-2945-6","article-title":"Pediatric glioblastoma: a single institution experience","volume":"32","author":"Nikitovi\u0107","year":"2016","journal-title":"Childs Nerv Syst"},{"key":"2025082803555950000_12.5.e227734.10","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s11060-017-2393-0","article-title":"Pediatric high-grade glioma: current molecular landscape and therapeutic approaches","volume":"134","author":"Braunstein","year":"2017","journal-title":"J Neurooncol"},{"key":"2025082803555950000_12.5.e227734.11","first-page":"153","article-title":"Pediatric high-grade glioma: biologically and clinically in need of new thinking","volume":"19","author":"Jones","year":"2017","journal-title":"Neuro Oncol"},{"key":"2025082803555950000_12.5.e227734.12","doi-asserted-by":"publisher","DOI":"10.2217\/cns.14.43"},{"key":"2025082803555950000_12.5.e227734.13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.16669"},{"key":"2025082803555950000_12.5.e227734.14","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003993","article-title":"Role of p53 isoforms and aggregations in cancer","volume":"95","author":"Kim","year":"2016","journal-title":"Medicine"},{"key":"2025082803555950000_12.5.e227734.15","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026187"},{"key":"2025082803555950000_12.5.e227734.16","doi-asserted-by":"publisher","DOI":"10.3171\/jns.2006.105.3.418"},{"key":"2025082803555950000_12.5.e227734.17","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/10.25.2889"},{"key":"2025082803555950000_12.5.e227734.18","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jocn.2014.12.001","article-title":"Glioblastoma in the setting of tuberous sclerosis","volume":"22","author":"Reyes","year":"2015","journal-title":"J Clin Neurosci"},{"key":"2025082803555950000_12.5.e227734.19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11060-017-2708-1","article-title":"Development of the CNS TAP tool for the selection of precision medicine therapies in neuro-oncology","volume":"137","author":"Linzey","year":"2018","journal-title":"J Neurooncol"},{"key":"2025082803555950000_12.5.e227734.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61134-9"},{"key":"2025082803555950000_12.5.e227734.21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70489-9"},{"key":"2025082803555950000_12.5.e227734.22","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-1068-8"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2018-227734","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T10:56:11Z","timestamp":1756378571000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2018-227734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,31]]},"references-count":22,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,5,31]]},"published-print":{"date-parts":[[2019,5,31]]}},"alternative-id":["10.1136\/bcr-2018-227734"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2018-227734","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,31]]}}}